Cubist wins FDA nod for antibiotic Zerbaxa
This article was originally published in Scrip
Executive Summary
Before its acquisition of Cubist Pharmaceuticals was barely underway, Merck's 9.5bn bid for the company already has garnered it a nice payoff – the US approval on 19 December of Zerbaxa (ceftolozane/tazobactam), a new combination antibiotic intended to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).